

Title: Gastric neuroendocrine tumor presenting with carcinoid syndrome

Authors: Luís Miguel Relvas, Tânia Gago, Francisco Velasco, Sónia Barros, Isabel Carvalho, Bruno Peixe

DOI: 10.17235/reed.2024.10364/2024 Link: <u>PubMed (Epub ahead of print)</u>

Please cite this article as:

Relvas Luís Miguel, Gago Tânia, Velasco Francisco, Barros Sónia, Carvalho Isabel, Peixe Bruno. Gastric neuroendocrine tumor presenting with carcinoid syndrome. Rev Esp Enferm Dig 2024. doi: 10.17235/reed.2024.10364/2024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Gastric neuroendocrine tumor presenting with carcinoid syndrome

Luís Miguel Relvas, Serviço de Gastrenterologia, Unidade Local de Saúde do Algarve – Unidade de Faro, Faro, Portugal Tânia Gago, Serviço de Gastrenterologia, Unidade Local de Saúde do Algarve – Unidade de Faro, Faro, Portugal Francisco Velasco, Serviço de Gastrenterologia, Unidade Local de Saúde do Algarve – Unidade de Faro, Faro, Portugal Sónia Barros, Serviço de Gastrenterologia, Unidade Local de Saúde do Algarve – Unidade de Faro, Faro, Portugal Isabel Malta Carvalho, Serviço de Gastrenterologia, Unidade Local de Saúde do Algarve – Unidade de Faro, Faro, Portugal Bruno Peixe, Serviço de Gastrenterologia, Unidade Local de Saúde do Algarve – Unidade de Faro, Faro, Portugal

Corresponding author; E-mail: <u>luismiguelrelvas@gmail.com</u>; Tel.: +351967984955

Keywords: Carcinoid tumors. Carcinoid syndrome. Gastric tumors.

Dear Editor,

We present the case of a 51-year-old male patient with a medical history of arterial hypertension and diabetes mellitus. He was referred to our clinic due to epigastric pain and significant weight loss (approximately 20 kg in one year). Additionally, he reported experiencing episodes of diarrhea, sweating, and flushing (Fig. 1A). On physical examination, jaundice, facial telangiectasias, and firm nodular hepatomegaly were noted, with no ascites. Analytically, there was an elevation in transaminases and cholestatic enzymes (AST 65 IU/L, ALT 147 IU/L, GGT 1511 IU/L, FA 472 IU/L) and total bilirubin of 6 mg/dL. Computed tomography revealed hepatomegaly with numerous hypodense nodular formations dispersed throughout the parenchyma, suggestive of secondary lesions (Fig. 1B). Upper digestive endoscopy identified an edematous and eroded fold in the gastric fundus (Fig. 1C), biopsied, with histological findings



consistent with a well-differentiated neuroendocrine tumor. Due to limited sample availability, evaluation of proliferative indices was not feasible, prompting a liver metastasis biopsy (Fig. 1D), which confirmed positivity for CAM 5.2, synaptophysin, chromogranin, and CD56. The Ki-67 labeling index was 25% (NET G3). Elevated levels of hydroxyindoleacetic acid and chromogranin A (11mg/24 hours and 52.5nmol/L, respectively), as well as CA 19.9 (395 U/ml), were observed, while other tumor markers remained within normal limits. Immediate action octreotide therapy (100 mcg every 12 hours) was initiated, leading to clinical improvement. Subsequently, prolonged-release octreotide (20 mg intramuscularly every four weeks) was adopted due to escalating symptoms. The patient continues to maintain symptom control under long-acting octreotide and has been referred to a neuroendocrine tumor reference center.

DISCUSSION

Neuroendocrine tumors (NETs) are rare neoplasms, predominantly occurring in the gastrointestinal tract, characterized by the production of neuroendocrine mediators [1][2]. Carcinoid syndrome (CS), a subset of NETs, manifests as a constellation of symptoms resulting from systemic release of these mediators. CS symptoms include diarrhea, flushing, abdominal pain, valvular heart disease, palpitations, telangiectasia, wheezing, weight loss, and pellagra. Gastric neuroendocrine tumors rarely present with classical CS symptoms [2][3]. Patients with gastrointestinal NETs and CS necessitate targeted management of their hormonal symptoms to improve their diminished quality of life. Prompt recognition of symptoms is crucial for tailored management [3][4].

Somatostatin, a peptide inhibiting the secretion of various hormones, binds to somatostatin receptors expressed on most NETs. Consequently, somatostatin analogues such as octreotide and lanreotide effectively suppress serotonin and other vasoactive substance release. Symptomatic relief, particularly in flushing and diarrhea, is achieved in over 80% of patients with carcinoid syndrome [3][5]. Therapy typically commences with short-acting subcutaneous octreotide; however, extended-release



formulations are preferred for initial management unless patients exhibit severe symptoms [5][6].

While widespread disease characterizes most cases of carcinoid syndrome, cytoreductive interventions such as surgical resection, ablation, or intra-arterial liver embolization may be considered in select cases. Resection or embolization of the majority of tumor bulk can induce biochemical responses and clinical benefits. The decision to pursue these options should consider factors such as serotonin overproduction, tumor growth rate, and somatostatin analogue efficacy. Importantly, somatostatin analogue initiation before interventional therapy reduces the risk of carcinoid crisis [6][7].

This case underscores the late manifestation of carcinoid syndrome in a patient with gastric tumor and liver metastasis, emphasizing the significance of recognizing the syndrome for improved symptom management and quality of life. Treatment involving somatostatin analogues, supplemented by surgery when feasible, can effectively control symptoms and optimize patient outcomes.

REFERENCES:

 Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. *Ann Surg*. 2004;240(1):117-122. doi:10.1097/01.sla.0000129342.67174.67
 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018;25(1):22-35. doi:10.1097/MED.00000000000376

3 - Varas Lorenzo M. Carcinoid syndrome and somatostatin analogues. Rev Esp Enferm Dig. 2023;115(12):726-727. doi:10.17235/reed.2023.9525/2023

4 - Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461-466.
doi:10.1097/MPA.0b013e3182328045

5 - Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. *J Clin Oncol*. 1999;17(2):600-606. doi:10.1200/JCO.1999.17.2.600



6 - Hofland J, Herrera-Martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. *Endocr Relat Cancer*. 2019;26(3):R145-R156. doi:10.1530/ERC-18-0495

7 - Kaltsas G, Caplin M, Davies P, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):245-254. doi:10.1159/000461583




Fig. 1 - A - Patient presenting flushing; B - CT showing multiple metastases; C - Endoscopic image of the lesion; D - Histology of liver metastasis.